Investor Presentaiton
Investor presentation
ADA 2019
Slide 7
Key inclusion criteria defining established CVD differ between GLP-1
CVOTs but trial populations are more comparable with aligned definitions
Key inclusion criteria defining established
cardiovascular disease across selected CVOTS
Established
CVD
Without
established
CVD
REWIND
21 prior CVD
MI
Ischaemic stroke
Revascularisation.*
Hospitalisation for
unstable angina
Myocardial ischaemia
PCI
Age 50 to 54 years,
with 21 prior CVD
Age 55 to 60 years, the
above, or evidence of
other vascular or renal
disease
Age ≥60 years, the
above, or 2 CV risk
factors
LEADER/SUSTAIN 63
21 of the following:
•
CVD
CeVD
PVD
Chronic HF (NYHA
class II or III)
Chronic kidney
disease of stage 3 or
higher
LEADER: age ≥50 years
with 21 prior CVD
SUSTAIN 6: age ≥50
years with clinical
evidence of CVD
LEADER: age ≥60 years
with 21 CV risk factor
SUSTAIN 6: age ≥60
years with subclinical
evidence of CVD
Trial population based on
previous MI/stroke vs CV risk factors
MI/Stroke
CV risk factors
22%¹
40%
41%
78%
60%
59%
REWIND
n=9,901
LEADER
n=9,340
Mean follow up:
5.4 years
Mean follow up:
3.8 years
SUSTAIN 6
n=3,297
Mean follow up:
2.1 years
*Coronary: carotid or peripheral; CeVD: cerebrovascular disease; CV; cardiovascular; CVD: cardiovascular disease; CVOT: cardiovascular outcomes trial; HF: heart failure; MI: myocardial infarction; NYHA: New York Heart Association; PCI:
percutaneous coronary intervention; PVD: peripheral vascular disease
1844; 5. 1. Gerstein HC et al. Diabetes Obes Metab 2017, Based on
1. Gerstein, HC et al. Diabetes Obes Metab 2017; doi:10.1111/dom. 13028; 2. Marso SP et al. N Engl J Med 2016;375 311-322; 3. Marso SP et al. N Engl J Med 2016;
Ischaemic stroke (5.3%) and Prior MI (16.2%);View entire presentation